\n<\/p>\n
Net
\nprofits HK$276 million; Interim dividend HK$0.05\/share<\/b><\/p>\n
\n
<\/p>\n
Continuous
\ninnovation & scientific research;<\/b><\/p>\n
Whole-industry-chain approach development<\/b>\u00a0<\/b>\u00a0<\/p>\n
Result summary:<\/b><\/p>\n HONG KONG SAR –\u00a0Media OutReach<\/a>\u00a0– 27 August 2021
During the first half
The Board of directors proposed to pay an interim dividend of HK$0.05
Amidst
In
Upholding the innovation-driven strategy and
Looking forward in the second half year, as the global
Mr. Qu Jiguang,
Net
profits HK$276 million; Interim dividend HK$0.05\/share
Continuous
innovation & scientific research; Whole-industry-chain approach development\u00a0\u00a0 Result summary: Total revenue HK$2,443 million, representing a growth of 37.0%; Net profits HK$276 million, representing a growth of 11.6%; The Board resolved to pay interim dividend of HK$0.05 \/share HONG KONG SAR –\u00a0Media OutReach\u00a0– 27 August 2021
…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/17222"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=17222"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/17222\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=17222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=17222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=17222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n– SSY Group Limited<\/a><\/b> (“SSY” or the
\n“Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”)
\npresents the interim results of the Company for the six months ended 30 June
\n2021.<\/p>\n
\n
<\/p>\n
\nof 2021, the Group achieved a revenue of HK$2,443 million, representing an increase
\nof 37.0% with gross profit
\nmargin 60.2%, representing a decrease of 3.8 percentage point compared to the
\ncorresponding period of last year. The Group achieved a net profit of HK$276 million,
\nrepresenting an increase of 11.6% compared to the corresponding period of last
\nyear. Amidst the normality under novel coronavirus epidemic domestically and
\ninternationally and despite the severe challenges brought by the unexpected
\noutbreak of the epidemic in Shijiazhuang in early 2021, the Group managed to
\ncope well with unfavorable factors arising from the epidemic with its endeavor
\nin production and implementation of various measures to ensure market support. The
\nGroup continued to promote its business strategy of scientific research,
\ninnovation and structural optimization, increased its effort in promoting the
\nformation of the operation pattern of integrated and collaborative development
\nin relation to the whole industry chain and diversified dosage forms from
\nmedical materials, bulk pharmaceuticals to high-end preparations. During the first
\nhalf year, the Group actively took measures to make new breakthroughs in
\nenhancing the market share of dominant products, and to accelerate the access
\nand growth of new preparation products and common bulk pharmaceuticals. Taking the opportunity brought by
\nNational Centralized Procurement as well as provincial and regional Group
\nPurchasing Organization Programme, the Group took various measures to
\nstrengthen the market-driven effect brought by the centralized procurement
\npolicy to continuously expand the market accessibility of the Group’s products.<\/p>\n
\n
\n
\n
<\/p>\n
\nper share for year 2021, which is unchanged from the corresponding period of
\nlast year. The total amount of
\ninterim dividend this year to be paid is approximately HK$151 million.<\/p>\n
\n
<\/p>\n
\nthe normality under epidemic, the supply and demand in the domestic
\npharmaceutical market was undergoing a gradual recovery, and the production and
\nsales of the Group’s infusion solutions, especially
\ntherapeutic infusion products, was showing a steady increase in growth. During
\nthe first half year, the sales volume of infusion solutions reached 632 million
\nbottles (bags), representing an increase of 31% compared to the corresponding
\nperiod of last year. The revenue of infusion solutions reached RMB1,273
\nmillion, representing an increase of 19% compared to the corresponding period
\nof last year. Ampoule products have become an important growth driver for the Group’s injection segment as it has become
\nincreasingly rich in varieties with its production and sales gradually scaled
\nup. During the first half year, the revenue of ampoule products was RMB406
\nmillion, representing an increase of 53%, which continued to maintain a rapid
\ngrowth momentum.<\/p>\n
\n
<\/p>\n
\nrespect of bulk pharmaceuticals business, the domestic and international market
\ndemand was showing a recovery growth. After continuous optimization and
\nimprovement of production process, transformation and enhancement of
\nenvironmental protection treatment capacity, the production capacities of the
\nGroup were released rapidly, and the product advantages such as cost and
\nquality were further demonstrated. Solid preparations business segment has been
\naccelerated its cultivation and expansion. Leveraging on tender awarded for
\nNational Centralized Procurement, the Group gradually enhanced the sales
\nproportion of solid preparations from year to year. In respect of medical
\nmaterials, Jiangsu Best New Medical Material Co., Ltd. continued to strengthen
\nthe build-up of innovation capability and enhance the supporting capacity of
\nthe downstream production chains in medical materials, which facilitate the
\nimprovement of production capacity and market coverage. Newly developed
\nmulti-layer co-extrusion bioprocessing films for single-use system in liquid
\ndosing, has been put into industrial production and resulted in sales. The
\nproduct is widely used in the fields of research and development and production
\nof vaccines and biopharmaceuticals. Currently, it is the only domestic
\nmanufacturer of bioprocessing films in China that can replace those imported
\nand has broad market development prospects.<\/p>\n
\n
<\/p>\n
\nbased on the cooperation with several universities and scientific research
\ninstitutes, the Group promoted scientific and technological innovation and
\naccelerated industrialization of scientific and technological achievements by
\nestablishing a technology platform of innovative drug research and development
\nintegrating production, education and research. Type 1 new drug NP-01, the
\nfirst innovative drug type of the Group, has completed sample preparation, and
\nits clinical trial research has fully commenced. The Group will continue to
\npush forward the preliminary research on anti-liver fibrosis Type 1 innovative
\ndrug AND-9, anti-epileptic compound QO-83 and anti-tumor Type 2 chemical
\ninnovative drug Miriplatin. During the first half of the year, a total of 7 production approvals were obtained for
\nvarious types of products. At present, the Group has submitted a total of 61
\nnew product projects for approval, including 35 items for liquid and solid
\npreparations, 13 products for consistency evaluation and 13 items for bulk
\npharmaceuticals, facilitating the changes of Group’s production and sales
\nstructure with the accumulated strength of innovation results. The research
\nresults of products for passing the consistency evaluations was convincing. 15
\ntypes with 20 product specifications of the Group passed consistency evaluation
\nor were regarded as passing the consistency evaluation.<\/p>\n
\n
<\/p>\n
\nepidemic is still evolving, the overall domestic and international economic
\nsituation remains complicated and dynamic. Facing the pressure arising from
\nexternal factors that may persist and bring new challenges to the Group’s production
\nand operation, the Group will continue to keep its composure, uphold its
\ndevelopment focus. The Group will also do its best in maintaining the momentum
\nin sustainable and stable development, promote development by innovation, and
\nimprove efficiency by management. Through the combination of the national and
\nprovincial Centralized Medicines Procurement, we will strive to do our best in
\nmarket access. The Group remains its leading position in the infusion market.
\nIn respect of the intravenous infusion solutions segment, we will ensure a
\nsignificant growth of its sales volume as compared to last year and continue to
\nstrengthen the proportion in sales of therapeutic and specialized infusion
\nproducts. At the same time, we will push forward the promotion and usage of
\nbioprocessing films in China, so as to strengthen the Group’s position in the
\nindustry and product influence in the field of medical materials. On the other
\nhand, with the goal of reducing costs and improving capacity utilization, we
\nwill actively cultivate and expand the bulk pharmaceuticals business. Moreover,
\nthe Group will adhere to the development idea of “combination of generic and
\ninnovative drugs” and will strengthen development of new types of oral
\npreparations, bulk pharmaceuticals and medical materials. Meanwhile, the Group
\nwill further develop the development and technology of bioprocessing films and
\nform core advantages of research and development of domestic bioprocessing film
\nproduction with comprehensive functions, sound system and leading technologies.<\/p>\n
\n
<\/p>\n
\nChairman and CEO of SSY Group Limited <\/b>said, “As one of the top 100 enterprises in
\nChina pharmaceutical industry and the top 30 best industrial enterprises with
\nChina pharmaceutical research and development product line, the Group will take
\nfull advantage of the market, policy opportunities arising from the positive
\nchanges in the domestic pharmaceutical market, we will firmly grasp the
\ninitiative of development, maintain the resilience and vitality of innovation
\nand development, overcome difficulties and tackle barriers, assume our mission
\nwith courage, and strive for facilitating the quality development of the Group.
\nBy virtue of the scale advantages, quality advantages, management advantages
\nand brand advantages accumulated in the industry over the years that
\ncontinuously stimulate innovation momentum, we firmly believe that we are
\npossible to bring satisfactory returns to our investors with stronger
\ndevelopment achievement.”<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"